Biofrontera Inc.

NasdaqCM BFRI

Biofrontera Inc. Debt to Equity Ratio for the Trailing 12 Months (TTM) ending September 30, 2024: 0.95

Biofrontera Inc. Debt to Equity Ratio is 0.95 for the Trailing 12 Months (TTM) ending September 30, 2024, a 515.13% change year over year. Debt to equity ratio represents the financing from debt versus equity. Higher ratio indicates more debt reliance, suggesting potential risk.

Biofrontera Inc. Debt to Equity Ratio for the Trailing 12 Months (TTM) ending September 30, 2023 was 0.15, a 0.00% change year over year.
Biofrontera Inc. Debt to Equity Ratio for the Trailing 12 Months (TTM) ending September 30, 2022 was 0.00.

Key data

Date	Debt to Equity Ratio	Debt to Income Ratio	Debt to Tangible Net Worth Ratio	Dividend Coverage Ratio

NasdaqCM: BFRI

Biofrontera Inc.

CEO	Dr. Hermann Luebbert Ph.D.
IPO Date	Oct. 29, 2021
Location	United States
Headquarters	120 Presidential Way
Employees	83
Sector	Health Care
Industries Pharmaceuticals Biotechnology Cosmetics Drugstores & Retail Pharmacies

Description

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, which is a prescription drug approved for use in combination with the company's licensor's medical device; and the RhodoLED lamp series for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also Xepi, a prescription cream for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

Key trends

Past 5 years